Topical vitamin D analogue calcipotriol reduces skin fibrosis in experimental scleroderma.
Vitamin D analogues can reduce TGF-β pro-fibrotic signaling in dermal fibroblasts, but they may also induce a potentially pro-fibrotic thymic stromal lymphopoietin (TSLP)-dependent Th2 cytokine local response. We have analyzed the net effect of topical vitamin D analogue calcipotriol (CPT) on the cytokine profile and the development of fibrosis in experimental model of bleomycin-induced fibrosis. Mice were simultaneously treated with topical CPT or vehicle cream and skin fibrosis was measured by collagen deposition, Masson's trichrome staining and hydroxyproline content. Cytokine and TSLP gene expression was evaluated by quantitative RT-PCR. We showed that in bleomycin injected skin, CPT administration significantly enhanced TSLP and IL-13 gene expression, but did not modify the expression of other cytokines. Skin fibrosis and hydroxyproline content were significantly reduced in CPT compared to vehicle-treated mice. In normal skin, topical administration of CPT lacked a direct pro-fibrotic effect. Our results demonstrate that topical CPT superinduces the expression of the TSLP/IL-13 Th2 axis in fibrotic skin, but it has a net anti-fibrotic effect. These data support the therapeutic use of topical vitamin D analogues for skin fibrosis.
Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (i+12), 28041, Madrid, Spain.
Alicia
A
Usategui
Gabriel
G
Criado
Manuel J
MJ
Del Rey
Regina
R
Faré
José L
JL
Pablos
D000287:Administration, Topical; D000818:Animals; D001761:Bleomycin / Q000008:administration & dosage; D002117:Calcitriol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003094:Collagen / Q000378:metabolism; D016207:Cytokines / Q000235:genetics / Q000378:metabolism; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004195:Disease Models, Animal; D005260:Female; D005355:Fibrosis; D006801:Humans; D006909:Hydroxyproline / Q000378:metabolism; D018793:Interleukin-13 / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008809:Mice, Inbred C3H; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000473:pathology*; D012867:Skin / Q000187:drug effects* / Q000473:pathology*; D015854:Up-Regulation; D000094632:Thymic Stromal Lymphopoietin
D016207:Cytokines; D003879:Dermatologic Agents; D018793:Interleukin-13; D001761:Bleomycin; C055085:calcipotriene; D003094:Collagen; D002117:Calcitriol; D006909:Hydroxyproline; D000094632:Thymic Stromal Lymphopoietin